A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

NCT03891524 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1242

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthroplasty, Replacement, Knee

Interventions

DRUG: JNJ-70033093 25 mg
DRUG: JNJ-70033093 50 mg
DRUG: JNJ-70033093 100 mg
DRUG: JNJ-70033093 200 mg
DRUG: Placebo
DRUG: Enoxaparin 40 mg

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]